Madrigal Pharmaceuticals Highlights Q2 Growth, Pipeline Expansion at Conference

Madrigal Pharmaceuticals Inc. (MDGL) presented its Q2 2026 performance and commercial progress at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026. The company’s lead drug, Rezdiffra, generated $364 million in sales, marking steady growth as it surpassed 50,000 patients on therapy—crossing that threshold in July 2026. Net patient additions averaged 6,000 to 7,000 per quarter, reflecting robust market penetration in the metabolic and liver disease space. Trading at $525.27 after a 3.91% drop from the prior close of $546.66, MDGL remains in focus amid its commercialization efforts and pipeline development.